 3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screeningrun-in period 4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screeningrun-in period, which in the opinion of the Investigator, may put the patient at risk because of hisher participation in the study, or may influence the results of the study, or the patients ability to complete entire duration of the study 